含表阿霉素的化疗方案治疗晚期乳腺癌28例分析

REGIMENS CONTAINING EPIRUBICIN IN ADVANCED BREAST CANCER REPORT OF 28 CASES

目的评估表阿霉素对晚期乳腺癌的临床疗效及安全性。方法随机采用５０ｍｇ／ｍ２、１００ｍｇ／ｍ２和１３５ｍｇ／ｍ２三个剂量级联合方案治疗２８例晚期乳腺癌患者。结果ＣＲ５例、ＰＲ１３例，有效率６４％；５０ｍｇ／ｍ２组９例，ＰＲ３例，１００ｍｇ／ｍ２组１３例，ＣＲ４例，ＰＲ６例；１３５ｍｇ／ｍ２组６例，ＣＲ１例，ＰＲ４例；随表阿素剂量增大有效率分别为３３％、７７％和８３％。不良反应主要是白细胞减少，随剂量强度增大而增高，５０ｍｇ／ｍ２组，Ⅰ度２２％；１００ｍｇ／ｍ２组Ⅰ、Ⅱ、Ⅲ、Ⅳ度分别为１５４％、３０％、１５４％、７６％，总发生率６９％。１３５ｍｇ／ｍ２组Ⅰ、Ⅱ、Ⅲ度分别为１６％、５０％和３３％，占１００％。肝、肾及心脏毒性轻微。结论高剂量ＥＰＩ用于晚期乳腺癌治疗，剂量强度与治疗效果呈正相关，但骨髓抑制亦随之增高，若以ＧＣＳＦ支持，可望取得更好量效关系。

PURPOSE Evaluation of clinical response and safety of epirubicin therapy in advanced breast cancer.METHODS 28 patients with advanced breast cancer were treated randomly with Epirubicin(EPI)containing regimens in 50 mg/m 2,100 mg/m 2and 135 mg/m 2,respectively.RESULTS 5 patients had complete remission(CR) and 13 partial remission(PR),an overall with response rate of 64%.The results showed that the response rate differences in the various dose groups of 50 mg/m 2、100 mg/m 2 and 135 mg/m 2 were highly significant.Their response rates were 33%、77% and 83%,respectively.The toxicity was leukopenia,the intensity increasing with dose leukopenia grade Ⅰ～Ⅳ in each group was 22%、69% and 100%,respectively.The hepatic、renal and cardiac toxicites were rather mild.CONCLUSION There was a relationship between the dose intensity and treatment results in advanced breast cancer with highdoses of epirubicin.With G CSF support,the results could be further improved.